5.62 USD
+0.08 (+1.44%)
At close: Jan 30, 2026
5.62 USD
0 (0%)
After Hours: 1/30/2026, 8:07:55 PM
ChartMill assigns a Buy % Consensus number of 53% to MYGN. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 7.85. This target is 39.75% above the current price.
- MYGN was analyzed by 18 analysts. The buy percentage consensus is at 53. So analysts seem to be rather neutral about MYGN.
- In the previous month the buy percentage consensus was at a similar level.
- MYGN was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-11-05 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-04 | TD Cowen | Maintains | Hold -> Hold |
| 2025-11-04 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-21 | ScotiaBank | Downgrade | Sector Outperform -> Sector Perform |
| 2025-05-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-08 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-05-07 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-07 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-05-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-09 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-04-01 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-03-12 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2025-03-04 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-03-03 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-02-25 | UBS | Maintains | Neutral -> Neutral |
| 2025-02-25 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-02-12 | Craig-Hallum | Initiate | Buy |
| 2025-01-30 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-01-28 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-16 | Stephens & Co. | Reiterate | Equal-Weight -> Equal-Weight |
| 2024-12-13 | B of A Securities | Maintains | Underperform -> Underperform |
| 2024-12-10 | UBS | Initiate | Neutral |
| 2024-12-09 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-11-18 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-09-19 | Morgan Stanley | Initiate | Equal-Weight |
| 2024-08-27 | Wells Fargo | Initiate | Overweight |
| 2024-08-13 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
MYRIAD GENETICS INC / MYGN FAQ
What is the average price target for MYRIAD GENETICS INC (MYGN) stock?
18 analysts have analysed MYGN and the average price target is 7.85 USD. This implies a price increase of 39.75% is expected in the next year compared to the current price of 5.62.
What is the consensus rating for MYGN stock?
The consensus rating for MYRIAD GENETICS INC (MYGN) is 53.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.